Alcoholic hepatitis secondary prevention

Jump to navigation Jump to search

Alcoholic hepatitis Microchapters


Patient Information


Historical Perspective



Differentiating Alcoholic hepatitis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray




Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alcoholic hepatitis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Alcoholic hepatitis secondary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alcoholic hepatitis secondary prevention

CDC on Alcoholic hepatitis secondary prevention

Alcoholic hepatitis secondary prevention in the news

Blogs on Alcoholic hepatitis secondary prevention

Directions to Hospitals Treating Alcoholic hepatitis

Risk calculators and risk factors for Alcoholic hepatitis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]


Disulfiram, naltrexone, and acamprosate are used to to maintain alcohol abstinence.Additionally, baclofen and gamma hydroxyl butyrate are options to reduce recidivism in patients with advanced chronic liver disease.

Secondary prevention


  1. Edwards S, Kenna GA, Swift RM, Leggio L (2011). "Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review". Curr Pharm Des. 17 (14): 1323–32. doi:10.2174/138161211796150765. PMID 21524263.
  2. Vanjak D, Samuel D, Gosset F, Derrida S, Moreau R, Soupison T; et al. (1989). "[Fulminant hepatitis induced by disulfiram in a patient with alcoholic cirrhosis. Survival after liver transplantation]". Gastroenterol Clin Biol. 13 (12): 1075–8. PMID 2625187.
  3. Volpicelli JR, Clay KL, Watson NT, O'Brien CP (1995). "Naltrexone in the treatment of alcoholism: predicting response to naltrexone". J Clin Psychiatry. 56 Suppl 7: 39–44. PMID 7673104.
  4. Liang R, Liu A, Perumpail RB, Wong RJ, Ahmed A (2015). "Advances in alcoholic liver disease: An update on alcoholic hepatitis". World J Gastroenterol. 21 (42): 11893–903. doi:10.3748/wjg.v21.i42.11893. PMC 4641111. PMID 26576078.
  5. Mason BJ (2005). "Acamprosate in the treatment of alcohol dependence". Expert Opin Pharmacother. 6 (12): 2103–15. doi:10.1517/14656566.6.12.2103. PMID 16197362.
  6. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A; et al. (2007). "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study". Lancet. 370 (9603): 1915–22. doi:10.1016/S0140-6736(07)61814-5. PMID 18068515.
  7. Caputo F, Bernardi M, Zoli G (2011). "Efficacy and safety of γ-hydroxybutyrate in treating alcohol withdrawal syndrome in an alcohol-dependent inpatient with decompensated liver cirrhosis: a case report". J Clin Psychopharmacol. 31 (1): 140–1. doi:10.1097/JCP.0b013e318203b36f. PMID 21192167.

Template:WikiDoc Sources